Nebido® interactive presentation

This guided interactive presentation takes you through the signs and symptoms of hypogonadism, the male patients who may have this condition in your practice, the implications of this condition on these men and how you can effectively manage these patients with Nebido®.

The presentation includes:

 

  • A prevalence calculator to help you identify undiagnosed hypogonadal patients in your practice with
    common co-morbidities such as T2DM, Obesity, CV risk factors and ED
  • Opportunity to Participate in 2 interactive Patient case studies to put your diagnostic and management skills to the test!
  • A chatbot with voice-over to guide you through the presentation

Hypogonadism prevalence calculator

Conditions like obesity, metabolic syndrome and T2DM are associated with lower levels of circulating testosterone. The BSSM guidelines recommend all patients with obesity or T2DM should be screened for TD and the European Association of Urology Guidelines also recommend screening these patients for TD.

The hypogonadism prevalence calculator is a useful tool that is included in this guided interactive presentation to help you establish the prevalence of hypogonadism amongst the men that you see in your daily practice.

Homeostatic model assessment for insulin resistance (HOMA-IR) tool


Quantify insulin resistance and beta-cell function of your patients.

Download

Treatment guidelines


Guidelines and recommendations issued by medical societies on the definition, investigation, treatment and follow-up of men with late-onset hypogonadism.

Find out more

Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk.

Adverse events should also be reported to Bayer plc, Tel: 01182063500, Fax: 01182063703, Email: pvuk@bayer.com.

If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc, Email: qualitycomplaints@bayer.com

For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.